Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease related to several comorbidities. Anxiety is an important comorbidity in PsA and the data is scarce. We aimed to understand the rates before biologic agents and change in anxiety with the treatment.
Methods: PsA patients from the Hacettepe University biologic database (HUR-BIO) were assessed for the high anxiety level (score ≥ 4) using the patient self-reported measure of anxiety on a 0-10 numerical scale, included in the Psoriatic Arthritis Impact of Disease questionnaire (PSAID-12). The rate and scores of anxiety were determined before starting biologic agents, at the first visit within 6 months. Changes in anxiety scores were assessed according to favorable treatment responses, and the correlation was evaluated by Spearman correlation analysis.
Results: From 520 patients registered, 147 [mean (SD) age 43.3 (12.4) years, 70.7% female] had anxiety score both at baseline and first visit within 6 months. Both the frequency of high anxiety level and mean (SD) scores decreased at the first visit [63.9% vs. 41.4%, 4.8 (3.4) vs. 3.2 (3.1) respectively, p < 0.001 for both] after a mean (SD) follow-up of 105.7 (22.2) days. There was also a positive correlation between the change in anxiety scores and all parameters tested for treatment response: pain, PGA, BASDAI, HAQ-DI, DAS-28, and also PsAID-12.
Conclusion: Anxiety is a more frequent problem at biologic initiation than rates observed in the general PsA population. The rates show a decreasing trend and correlates with treatment response but is still high within 6 months under treatment.
Key Points: • As high as 65% of patients had a high anxiety levels before the initiation of bDMARDs. • The disease activity control is essential in reducing anxiety; however, rates are still high within 6 months. • Decreased anxiety scores and rates of the high anxiety level are linked to better outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10067-021-06012-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Where we Live matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States.
Arthritis Rheumatol
September 2025
Washington DC Veterans Affairs Medical Center; Georgetown University, Washington, DC, USA.
Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.
Statistical Considerations Regarding the Association of Higher Levels of High-Sensitivity C-Reactive Protein With Future Development of Psoriatic Arthritis in Psoriasis.
Arthritis Care Res (Hoboken)
September 2025
Department of Clincial Laboratory, South China Hospital, Medical School, Shenzhen University, Shenzhen, Guangdong, China.
Effectiveness of Biologics on synovitis and enthesitis using Musculoskeletal ultrasound assessment in subclinical psoriatic arthritis: A 12-week observational real-world study.
J Am Acad Dermatol
September 2025
Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350000, People's Republic of China; Key Laboratory of skin cancer of Fujian higher education institutions, Fuzhou, Fujian 350000, People's Republic of China; Fujian Provincial Clinical Research Cent
Background: Psoriatic arthritis (PsA) is a condition that can lead to permanent joint deformities. It is crucial to find ways to prevent psoriasis (PsO) from progressing to PsA.
Objectives: To observe the short-term efficacy of biologics on synovitis and enthesitis in subclinical psoriatic arthritis (Sub-PsA) using musculoskeletal ultrasound (MSUS).
Association of Dry Eye and Corneal Ulcers With Collagen Vascular Diseases in a Medicare Population.
Cornea
September 2025
Icahn School of Medicine at Mount Sinai, Department of Ophthalmology, New York, NY.
Purpose: There is a lack of research on the extent to which non-Sjögren collagen vascular diseases affect the ocular surface. This study aims to understand the associations between collagen vascular diseases and dry eye and corneal ulcers.
Methods: This study analyzed a random 5% sample of national Medicare beneficiaries from 2011 to 2015 and included claims for those with collagen vascular diseases and either dry eye or corneal ulcers (n = 2,688,114).
Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.
JAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.